Single-Blind, Randomized, Controlled, Phase I/II Vaccination Study on Safety and Immunogenicity of a Recombinant MVA-HIV Polytope Vaccine (MVA-mBN32) in HIV-1 Infected Patients With CD4 Counts > 250/microl

Trial Profile

Single-Blind, Randomized, Controlled, Phase I/II Vaccination Study on Safety and Immunogenicity of a Recombinant MVA-HIV Polytope Vaccine (MVA-mBN32) in HIV-1 Infected Patients With CD4 Counts > 250/microl

Completed
Phase of Trial: Phase I/II

Latest Information Update: 14 Jul 2009

At a glance

  • Drugs EP 1232 (Primary)
  • Indications HIV infections; HIV-1 infections
  • Focus Adverse reactions; Pharmacodynamics
  • Sponsors Bavarian Nordic
  • Most Recent Events

    • 14 Jul 2009 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov
    • 14 Jul 2009 Actual end date (1 Jan 2009) added as reported by ClinicalTrials.gov.
    • 28 Dec 2007 Status changed from recruiting to in progress.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top